Literature DB >> 35685993

Genomic landscape of T-cell lymphoblastic lymphoma.

Zhaoming Li1, Yue Song1, Mingzhi Zhang1, Yiming Wei1,2, Hang Ruan1,2.   

Abstract

Objective: T-cell lymphoblastic lymphoma (T-LBL) is an aggressive neoplasm of precursor T cells, however, detailed genome-wide sequencing of large T-LBL cohorts has not been performed due to its rarity. The purpose of this study was to identify putative driver genes in T-LBL.
Methods: To gain insight into the genetic mechanisms of T-LBL development, we performed whole-exome sequencing on 41 paired tumor-normal DNA samples from patients with T-LBL.
Results: We identified 32 putative driver genes using whole-exome sequencing in 41 T-LBL cases, many of which have not previously been described in T-LBL, such as Janus kinase 3 (JAK3), Janus kinase 1 (JAK1), Runt-related transcription factor 1 (RUNX1) and Wilms' tumor suppressor gene 1 (WT1). When comparing the genetic alterations of T-LBL to T-cell acute lymphoblastic leukemia (T-ALL), we found that JAK-STAT and RAS pathway mutations were predominantly observed in T-LBL (58.5% and 34.1%, respectively), whereas Notch and cell cycle signaling pathways mutations were more prevalent in T-ALL. Notably, besides notch receptor 1 (NOTCH1), mutational status of plant homeodomain (PHD)-like finger protein 6 (PHF6) was identified as another independent factor for good prognosis. Of utmost interest is that co-existence of PHF6 and NOTCH1 mutation status might provide an alternative for early therapeutic stratification in T-LBL. Conclusions: Together, our findings will not only provide new insights into the molecular and genetic mechanisms of T-LBL, but also have tangible implications for clinical practice.
Copyright ©2022 Chinese Journal of Cancer Research. All rights reserved.

Entities:  

Keywords:  NOTCH1; PHF6; T-cell lymphoblastic lymphoma; mutation

Year:  2022        PMID: 35685993      PMCID: PMC9086577          DOI: 10.21147/j.issn.1000-9604.2022.02.03

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   4.026


  27 in total

1.  Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia.

Authors:  S T Balbach; O Makarova; B R Bonn; M Zimmermann; M Rohde; I Oschlies; W Klapper; C Rössig; B Burkhardt
Journal:  Leukemia       Date:  2015-07-28       Impact factor: 11.528

2.  Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL.

Authors:  Agnieszka A Wendorff; S Aidan Quinn; Marissa Rashkovan; Chioma J Madubata; Alberto Ambesi-Impiombato; Mark R Litzow; Martin S Tallman; Elisabeth Paietta; Maddalena Paganin; Giuseppe Basso; Julie M Gastier-Foster; Mignon L Loh; Raul Rabadan; Pieter Van Vlierberghe; Adolfo A Ferrando
Journal:  Cancer Discov       Date:  2018-12-19       Impact factor: 39.397

3.  Multiplex ligation-dependent probe amplification validates LOH6q analyses and enhances insight into chromosome 6q aberrations in pediatric T-cell lymphoblastic leukemia and lymphoma.

Authors:  Marius Rohde; Bettina R Bonn; Martin Zimmermann; Monika Szczepanowski; Christine Damm-Welk; Martin Stanulla; Birgit Burkhardt
Journal:  Leuk Lymphoma       Date:  2014-11-19

4.  Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma.

Authors:  Celine Callens; Frederic Baleydier; Etienne Lengline; Raouf Ben Abdelali; Arnaud Petit; Patrick Villarese; Agata Cieslak; Veronique Minard-Colin; Anne Rullier; Anne Moreau; André Baruchel; Claudine Schmitt; Vahid Asnafi; Yves Bertrand; Elizabeth Macintyre
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

5.  Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.

Authors:  E Waanders; V H J van der Velden; C E van der Schoot; F N van Leeuwen; S V van Reijmersdal; V de Haas; A J Veerman; A Geurts van Kessel; P M Hoogerbrugge; R P Kuiper; J J M van Dongen
Journal:  Leukemia       Date:  2010-11-19       Impact factor: 11.528

6.  Contemporary trends on expenditure of hospital care on total cancer and its subtypes in China during 2008-2017.

Authors:  Yue Cai; Wanqing Chen; Xiaoxu Wang; Xue Xia; Xiang Cui; Shiyong Wu; Jinghua Li
Journal:  Chin J Cancer Res       Date:  2021-10-31       Impact factor: 5.087

7.  Clinical and biological relevance of genetic alterations in pediatric T-cell acute lymphoblastic leukemia in Taiwan.

Authors:  Ting-Chi Yeh; Der-Cherng Liang; Hsi-Che Liu; Tang-Her Jaing; Shih-Hsiang Chen; Jen-Yin Hou; Chao-Ping Yang; Ying-Jung Huang; Hsien-Wen Yao; Ting-Yu Huang; Tung-Huei Lin; Lee-Yung Shih
Journal:  Pediatr Blood Cancer       Date:  2018-10-02       Impact factor: 3.167

8.  PHF6 mutations in T-cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Teresa Palomero; Hossein Khiabanian; Joni Van der Meulen; Mireia Castillo; Nadine Van Roy; Barbara De Moerloose; Jan Philippé; Sara González-García; María L Toribio; Tom Taghon; Linda Zuurbier; Barbara Cauwelier; Christine J Harrison; Claire Schwab; Markus Pisecker; Sabine Strehl; Anton W Langerak; Jozef Gecz; Edwin Sonneveld; Rob Pieters; Elisabeth Paietta; Jacob M Rowe; Peter H Wiernik; Yves Benoit; Jean Soulier; Bruce Poppe; Xiaopan Yao; Carlos Cordon-Cardo; Jules Meijerink; Raul Rabadan; Frank Speleman; Adolfo Ferrando
Journal:  Nat Genet       Date:  2010-03-14       Impact factor: 38.330

9.  Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies.

Authors:  A Renneville; S Kaltenbach; E Clappier; S Collette; J-B Micol; B Nelken; P Lepelley; N Dastugue; Y Benoît; Y Bertrand; C Preudhomme; H Cavé
Journal:  Leukemia       Date:  2009-10-22       Impact factor: 11.528

10.  Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version).

Authors:  Jun Zhu; Jun Ma
Journal:  Chin J Cancer Res       Date:  2021-06-30       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.